Risk of malignancy in dermatomyositis and polymyositis: A systematic review and meta-analysis

Journal of Cutaneous Medicine and Surgery

Volumn 21, Issue 2, 2017, Pages 131-136

  Qiang, Judy K ^a   Kim, Whan B ^b   Baibergenova, Akerke ^a   Alhusayen, Raed ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

dermatomyositis; malignancy; meta analysis; polymyositis; risk

Indexed keywords

AGE; ALCOHOL CONSUMPTION; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; DERMATOMYOSITIS; ETHNICITY; GENDER; HUMAN; LUNG CANCER; META ANALYSIS; NONHODGKIN LYMPHOMA; OVARY CANCER; PARANEOPLASTIC SYNDROME; POLYMYOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; SMOKING; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW; INCIDENCE; NEOPLASMS; RISK FACTOR; SEX DIFFERENCE; TIME FACTOR;

AGE FACTORS; DERMATOMYOSITIS; HUMANS; INCIDENCE; NEOPLASMS; POLYMYOSITIS; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 85018189724     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/1203475416665601     Document Type: Article

References (22)

1. Benbassat J, Geffel D, Zlotnick A. Epidemiology of polymyositis-dermatomyositis in Israel, 1960-76. Isr J Med Sci. 1980;16:197-200.
2. Medsger TA Jr, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715-723.
3. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21(10):1855-1859.
4. Stertz G. Polymyositis. Berl Klin Wochenschr. 1916;53:489.
5. Yang Z, Lin F, Oin B, et al. Polymyositis/dermatomyositis and malignancy risk: A metaanalysis study. J Rheumatol. 2015;42(2):282-291.
6. Chen D, Yuan S, Wu X, et al. Incidence and predictive factors for malignancies with dermatomyositis: A cohort from southern China. Clin Exp Rheumatol. 2014;32(5):615-621.
7. Yang SY, Cha BK, Kim G, et al. Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma. Korean J Intern Med. 2014;29(2):231-235.
8. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-prove inflammatory myopathy: A populationbased cohort study. Ann Intern Med. 2001;134(12):1087-1095.
9. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet. 2001;357(9250):96-100.
10. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study. Br J Cancer. 2001;85(1):41-45.
11. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: A nationwide cohort study in Taiwan. Arthritis Res Ther. 2010; 12(2):R70.
12. Limaye V, Luke C, Tucker G, et al. The incidence and associations of malignancy in a large cohort of patients with biopsydetermined idiopathic inflammatory myositis. Rheumatol Int. 2013;33(4):965-971.
13. Kuo CF, See LC, Yu KH, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: A nationwide population study. Br J Dermatol. 2011;165: 1273-1279.
14. Liu WC, Ho M, Koh WP, et al. An 11-year review of dermatomyositis in Asian patients. Ann Acad Med Singapore. 2010;39:843-847.
15. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201(4):591.
16. Callen JP, Wortmann R. Dermatomyositis. Clin Dermatol. 2006;24(5):363-373.
17. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer?. Arch Dermatol. 2002;138(7):969-971.
18. So MW, Koo BS, Kim YG, et al. Idiopathic inflammatory myopathy associated with malignancy: A retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol. 2011;38:2432-2435.
19. Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol. 2011;21:178-183.
20. Antiochos BB, Brown LA, Li Z, et al. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol. 2009;36:2704-2710.
21. Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine. 2009;88:91-97.
22. Olazagasti JM, Baez PJ, Wetter DA, et al. Cancer risk in dermatomyositis: A meta-analysis of cohort studies. Am J Clin Dermatol. 2015;16(2):89-98.